242 related articles for article (PubMed ID: 19476859)
1. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
Olson JA; Budd GT; Carey LA; Harris LA; Esserman LJ; Fleming GF; Marcom PK; Leight GS; Giuntoli T; Commean P; Bae K; Luo J; Ellis MJ
J Am Coll Surg; 2009 May; 208(5):906-14; discussion 915-6. PubMed ID: 19476859
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
Krainick-Strobel UE; Lichtenegger W; Wallwiener D; Tulusan AH; Jänicke F; Bastert G; Kiesel L; Wackwitz B; Paepke S
BMC Cancer; 2008 Feb; 8():62. PubMed ID: 18302747
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Grassadonia A; Di Nicola M; Grossi S; Noccioli P; Tavoletta S; Politi R; Angelucci D; Marinelli C; Zilli M; Ausili Cefaro G; Tinari N; De Tursi M; Iezzi L; Cioffi P; Iacobelli S; Natoli C; Cianchetti E
Ann Surg Oncol; 2014 May; 21(5):1575-82. PubMed ID: 24522992
[TBL] [Abstract][Full Text] [Related]
4. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery.
Carpenter R; Doughty JC; Cordiner C; Moss N; Gandhi A; Wilson C; Andrews C; Ellis G; Gui G; Skene AI
Breast Cancer Res Treat; 2014 Apr; 144(3):569-76. PubMed ID: 24562823
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
[TBL] [Abstract][Full Text] [Related]
6. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery.
Woeste MR; Bhutiani N; Donaldson M; McMasters KM; Ajkay N
J Surg Oncol; 2021 Feb; 123(2):439-445. PubMed ID: 33259649
[TBL] [Abstract][Full Text] [Related]
8. Letrozole in the neoadjuvant setting: the P024 trial.
Ellis MJ; Ma C
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):33-43. PubMed ID: 17912634
[TBL] [Abstract][Full Text] [Related]
9. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Barbie TU; Ma C; Margenthaler JA
Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
[TBL] [Abstract][Full Text] [Related]
10. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
[TBL] [Abstract][Full Text] [Related]
11. Predictors of re-excision among women undergoing breast-conserving surgery for cancer.
Waljee JF; Hu ES; Newman LA; Alderman AK
Ann Surg Oncol; 2008 May; 15(5):1297-303. PubMed ID: 18259820
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG).
Skriver SK; Laenkholm AV; Rasmussen BB; Handler J; Grundtmann B; Tvedskov TF; Christiansen P; Knoop AS; Jensen MB; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):31-37. PubMed ID: 29168427
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA
J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689
[TBL] [Abstract][Full Text] [Related]
14. The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy.
Mazouni C; Naveau A; Kane A; Dunant A; Garbay JR; Leymarie N; Sarfati B; Delaloge S; Rimareix F
Breast; 2013 Dec; 22(6):1189-93. PubMed ID: 24054903
[TBL] [Abstract][Full Text] [Related]
15. Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
Ramalingam K; Clelland E; Rothschild H; Mujir F; Record H; Kaur M; Mukhtar RA
Ann Surg Oncol; 2023 Nov; 30(12):7099-7106. PubMed ID: 37561345
[TBL] [Abstract][Full Text] [Related]
16. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
Cocquyt VF; Blondeel PN; Depypere HT; Praet MM; Schelfhout VR; Silva OE; Hurley J; Serreyn RF; Daems KK; Van Belle SJ
Eur J Surg Oncol; 2003 May; 29(4):361-7. PubMed ID: 12711290
[TBL] [Abstract][Full Text] [Related]
17. Preoperative chemotherapy for T2 breast cancer is associated with improved surgical outcome.
Karanlik H; Ozgur I; Cabioglu N; Sen F; Erturk K; Kilic B; Onder S; Deniz M; Yavuz E; Aydiner A
Eur J Surg Oncol; 2015 Sep; 41(9):1226-33. PubMed ID: 26141784
[TBL] [Abstract][Full Text] [Related]
18. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer.
Petrelli F; Barni S
Breast Cancer Res Treat; 2013 Nov; 142(2):227-35. PubMed ID: 24177758
[TBL] [Abstract][Full Text] [Related]
19. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Novoa Vargas A; Font López KC; Amador DD
Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
[TBL] [Abstract][Full Text] [Related]
20. Challenges in the endocrine management of breast cancer.
Mouridsen HT; Rose C; Brodie AH; Smith IE
Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]